Lumbar intervertebral disc degeneration
Conditions
Interventions
Experimental group (Arginine group):Intravenous infusion of arginine hydrochloride injection (initiated within 3–7 days after baseline assessment, once weekly for 4 consecutive weeks, 4 infusions in t
Control group (Placebo group):An equal volume of 1000?mL 0.9% sodium chloride injection (normal saline) was administered intravenously, initiated within 3–7 days after baseline assessment, once weekly
Sponsors
The Seventh Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with disc degenerative low back pain admitted between April 2026 and December 2026, with symptom duration >= 3 months, Visual Analogue Scale (VAS) score >= 2 in the past week, and who have signed the informed consent form. 2.Aged 18 to 65 years.
Exclusion criteria
Exclusion criteria: 1. Age under 18 or over 65 years; 2. Individuals with medical contraindications to research-use arginine; 3. Those with severe liver or kidney dysfunction, coagulation disorders, anuria, or hyperchloremic acidosis; 4. History of gastrointestinal ulcer bleeding or intracranial hemorrhage within the past 3 months, or currently taking anticoagulant medications (such as warfarin or rivaroxaban); 5. Individuals with mental illness, malignant tumors, or other severe systemic diseases who cannot tolerate interventions or follow-up; 6. Pregnant or breastfeeding women, or those planning to become pregnant during the follow-up period; 7. Other situations that, after physician assessment, are considered high-risk for medication and should be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference between groups in the proportion of patients showing improvement in disc imaging within 90 days of pre-treatment; | — |
Countries
China
Contacts
Public ContactFuxin Wei
The Seventh Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed